Molecular and genetic basis of sudden cardiac death

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 75-83

  George, Alfred L ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCEROL 3 PHOSPHATE DEHYDROGENASE; POTASSIUM CHANNEL HERG; RYANODINE RECEPTOR 2;

ANDERSEN SYNDROME; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; DISEASE PREDISPOSITION; EXCITATION CONTRACTION COUPLING; GENETIC ASSOCIATION; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART EXCITATION; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART MUSCLE POTENTIAL; HEART RHYTHM; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE CONDUCTION; HUMAN; ION CURRENT; LONG QT SYNDROME; MOLECULAR GENETICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SHORT QT SYNDROME; SUDDEN DEATH; TORSADE DES POINTES;

EID: 84873828284     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI62928     Document Type: Review

References (130)

1. Fishman GI, et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation. 2010;122(22): 2335-2348.
2. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104(18): 2158-2163.
3. Lehnart SE, et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation. 2007;116(20): 2325-2345.
4. George AL Jr. Common genetic variants in sudden cardiac death. Heart Rhythm. 2009;6(11 suppl):S3-S9.
5. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation. 2012;125(4): 620-637.
6. Auerbach DS, Grzda KR, Furspan PB, Sato PY, Mironov S, Jalife J. Structural heterogeneity promotes triggered activity, reflection and arrhythmogenesis in cardiomyocyte monolayers. J Physiol. 2011;589(pt 9): 2363-2381.
7. Vaquero M, Calvo D, Jalife J. Cardiac fibrillation: from ion channels to rotors in the human heart. Heart Rhythm. 2008;5(6): 872-879.
8. Antzelevitch C, Yan GX, Shimizu W. Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome. J Electrocardiol. 1999;32(suppl): 158-165.
9. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100(15): 1660-1666.
10. January CT, Fozzard HA. Delayed afterdepolarizations in heart muscle: mechanisms and relevance. Pharmacol Rev. 1988;40(3): 219-227.
11. January CT, Moscucci A. Cellular mechanisms of early afterdepolarizations. Ann N Y Acad Sci. 1992;644: 23-32.
12. Wu Y, Roden DM, Anderson ME. Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. Circ Res. 1999;84(8): 906-912.
13. McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest. 2013;123(1): 19-26.
14. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation. 1978;57(6): 1074-1077.
15. Chugh SS, et al. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009; 119(5): 663-670.
16. Vincent GM. The molecular genetics of the long QT syndrome: Genes causing fainting and sudden death. Annu Rev Med. 1998;49: 263-274.
17. Schwartz PJ, et al. Prevalence of the congenital long- QT syndrome. Circulation. 2009;120(18): 1761-1767.
18. Curran ME, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80(5): 795-803.
19. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81(2): 299-307.
20. Wang Q, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996;12(1): 17-23.
21. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet. 1997;17(3): 338-340.
22. Abbott GW, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell. 1999;97(2): 175-187.
23. Schulze-Bahr E, et al. KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet. 1997;17(3): 267-268.
24. Wang Q, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80(5): 805-811.
25. Medeiros-Domingo A, et al. SCN4B-encoded sodium channel β4 subunit in congenital long-QT syndrome. Circulation. 2007;116(2): 134-142.
26. Splawski I, et al. CaV1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004;119(1): 19-31.
27. Plaster NM, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001;105(4): 511-519.
28. Yang Y, et al. Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet. 2010;86(6): 872-880.
29. Mohler PJ, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003;421(6923): 634-639.
30. Vatta M, et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation. 2006;114(20): 2104-2112.
31. Chen L, Marquardt ML, Tester DJ, Sampson KJ, Ackerman MJ, Kass RS. Mutation of an A-kinaseanchoring protein causes long-QT syndrome. Proc Natl Acad Sci U S A. 2007;104(52): 20990-20995.
32. Cheng J, et al. Alpha1-syntrophin mutations identified in sudden infant death syndrome cause an increase in late cardiac sodium current. Circ Arrhythm Electrophysiol. 2009;2(6): 667-676.
33. Splawski I, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000;102(10): 1178-1185.
34. Sesti F, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A. 2000;97(19): 10613-10618.
35. Neyroud N, et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Genet. 1997;15(2): 186-189.
36. Furutani M, et al. Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation. 1999;99(17): 2290-2294.
37. Anderson CL, et al. Most LQT2 mutations reduce KV11.1 (hERG) current by a class 2 (trafficking- deficient) mechanism. Circulation. 2006; 113(3): 365-373.
38. Rajamani S, Anderson CL, Anson BD, January CT. Pharmacological rescue of human K+ channel long-QT2 mutations: human ether-a-go-gorelated gene rescue without block. Circulation. 2002;105(24): 2830-2835.
39. Brunner M, et al. Mechanisms of cardiac arrhythmias and sudden death in transgenic rabbits with long QT syndrome. J Clin Invest. 2008;118(6): 2246-2259.
40. Arnaout R, et al. Zebrafish model for human long QT syndrome. Proc Natl Acad Sci U S A. 2007; 104(27): 11316-11321.
41. Kapplinger JD, et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009; 6(9): 1297-1303.
42. Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995;376(6542): 683-685.
43. Ueda K, et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci U S A. 2008;105(27): 9355-9360.
44. Nuyens D, et al. Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat Med. 2001;7(9): 1021-1027.
45. Schwartz PJ, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate - Implications for gene-specific therapy. Circulation. 1995;92(12): 3381-3386.
46. Wang DW, Yazawa K, Makita N, George AL Jr, Bennett PB. Pharmacological targeting of long QT mutant sodium channels. J Clin Invest. 1997; 99(7): 1714-1720.
47. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol. 2006;148(1): 16-24.
48. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;19(12): 1289-1293.
49. Kannankeril P, Roden DM, Darbar D. Druginduced long QT syndrome. Pharmacol Rev. 2010; 62(4): 760-781.
50. Itoh H, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long- QT syndrome. Circ Arrhythm Electrophysiol. 2009; 2(5): 511-523.
51. Ramire AH, et al. Novel rare variants in congenital cardiac arrhythmia genes are frequent in druginduced torsades de pointes [published online ahead of print May 15, 2012]. Pharmacogenomics J. doi:10.1038/tpj.2012.14.
52. Kääb S, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet. 2011;5(1): 91-99.
53. Roden DM. Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med. 2006;259(1): 59-69.
54. Yang P, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105(16): 1943-1948.
55. Liu K, et al. New mechanism contributing to druginduced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation. 2005;112(21): 3239-3246.
56. Crotti L, et al. Torsades de pointes following acute myocardial infarction: Evidence for a deadly link with a common genetic variant. Heart Rhythm. 2012;9(7): 1104-1112.
57. Tawil R, et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol. 1994;35(3): 326-330.
58. Yoon G, et al. Andersen-Tawil syndrome: Prospective cohort analysis and expansion of the phenotype. Am J Med Genet A. 2006;140(4): 312-321.
59. Andelfinger G, Tapper AR, Welch RC, Vanoye CG, George AL Jr, Benson DW. KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes. Am J Hum Genet. 2002;71(3): 663-668.
60. Zhang L, et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation. 2005; 111(21): 2720-2726.
61. Hosaka Y, et al. Function, subcellular localization and assembly of a novel mutation of KCNJ2 in Andersen's syndrome. J Mol Cell Cardiol. 2003;35(4): 409-415.
62. Tristani-Firouzi M, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest. 2002;110(3): 381-388.
63. Zobel C, et al. Molecular dissection of the inward rectifier potassium current IK1 in rabbit cardiomyocytes: evidence for heteromeric co-assembly of Kir2.1 and Kir2.2. J Physiol. 2003;550(pt 2): 365-372.
64. Zaritsky JJ, Redell JB, Tempel BL, Schwarz TL. The consequences of disrupting cardiac inwardly rectifying K+ current IK1 as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes. J Physiol. 2001;533(pt 3): 697-710.
65. Miake J, Marban E, Nuss HB. Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression. J Clin Invest. 2003;111(10): 1529-1536.
66. Donaldson MR, et al. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology. 2003;60(11): 1811-1816.
67. Bendahhou S, Donaldson MR, Plaster NM, Tristani-Firouzi M, Fu YH, Ptácek LJ. Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome. J Biol Chem. 2003; 278(51): 51779-51785.
68. Ballester LY, et al. Trafficking-competent and trafficking- defective KCNJ2 mutations in Andersen syndrome. Hum Mutat. 2006;27(4):388.
69. Zaritsky JJ, Eckman DM, Wellman GC, Nelson MT, Schwarz TL. Targeted disruption of Kir2.1 and Kir2.2 genes reveals the essential role of the inwardly rectifying K+ current in K+-mediated vasodilation. Circ Res. 2000;87(2): 160-166.
70. Tsuboi M, Antzelevitch C. Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm. 2006;3(3): 328-335.
71. Morita H, Zipes DP, Morita ST, Wu J. Mechanism of U wave and polymorphic ventricular tachycardia in a canine tissue model of Andersen-Tawil syndrome. Cardiovasc Res. 2007;75(3): 510-518.
72. Splawski I, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A. 2005;102(23): 8089-8096.
73. Barrett CF, Tsien RW. The Timothy syndrome mutation differentially affects voltage- and calcium- dependent inactivation of CaV1.2 L-type calcium channels. Proc Natl Acad Sci U S A. 2008; 105(6): 2157-2162.
74. Thiel WH, et al. Proarrhythmic defects in Timothy syndrome require calmodulin kinase II. Circulation. 2008;118(22): 2225-2234.
75. Gaita F, et al. Short QT Syndrome: a familial cause of sudden death. Circulation. 2003;108(8): 965-970.
76. Bellocq C, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation. 2004;109(20): 2394-2397.
77. Brugada R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2004;109(1): 30-35.
78. Priori SG, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res. 2005;96(7): 800-807.
79. Antzelevitch C, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;115(4): 442-449.
80. Templin C, et al. Identification of a novel lossof- function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J. 2011; 32(9): 1077-1088.
81. Hassel D, et al. Deficient zebrafish ether-a-gogo- related gene channel gating causes short-QT syndrome in zebrafish reggae mutants. Circulation. 2008;117(7): 866-875.
82. Casini S, Postma AV. Decreased inward rectification of Kir2.1 channels is a novel mechanism underlying the short QT syndrome. Cardiovasc Res. 2012; 93(4): 535-536.
83. Brugada J, Brugada R, Brugada P. Right bundlebranch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation. 1998;97(5): 457-460.
84. Brugada R, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101(5): 510-515.
85. Keller DI, et al. A novel SCN5A mutation, F1344S, identified in a patient with Brugada syndrome and fever-induced ventricular fibrillation. Cardiovasc Res. 2006;70(3): 521-529.
86. Vatta M, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet. 2002;11(3): 337-345.
87. Baron RC, Thacker SB, Gorelkin L, Vernon AA, Taylor WR, Choi K. Sudden death among Southeast Asian refugees. An unexplained nocturnal phenomenon. JAMA. 1983;250(21): 2947-2951.
88. Nademanee K, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation. 1997;96(8): 2595-2600.
89. Poelzing S, et al. SCN5A polymorphism restores trafficking of a Brugada syndrome mutation on a separate gene. Circulation. 2006;114(5): 368-376.
90. Leoni AL, et al. Variable NaV1.5 protein expression from the wild-type allele correlates with the penetrance of cardiac conduction disease in the Scn5a+/- mouse model. PLoS One. 2010;19(2):e9298.
91. Ohno S, et al. KCNE5 (KCNE1L) Variants are novel modulators of Brugada syndrome and idiopathic ventricular fibrillation. Circ Arrhythm Electrophysiol. 2011;4(3): 352-361.
92. Chen Q, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392(6673): 293-296.
93. Schulze-Bahr E, et al. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat. 2003;21(6): 651-652.
94. Baroudi G, Acharfi S, Larouche C, Chahine M. Expression and intracellular localization of an SCN5A double mutant R1232W/T1620M implicated in Brugada syndrome. Circ Res. 2002; 90(1):E11-E16.
95. Baroudi G, Pouliot V, Denjoy I, Guicheney P, Shrier A, Chahine M. Novel mechanism for Brugada syndrome: defective surface localization of an SCN5A mutant (R1432G). Circ Res. 2001;88(12):E78-E83.
96. Valdivia CR, et al. A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. Cardiovasc Res. 2004;62(1): 53-62.
97. Dumaine R, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res. 1999;85(9): 803-809.
98. Wang DW, Makita N, Kitabatake A, Balser JR, George AL Jr. Enhanced Na+ channel intermediate inactivation in Brugada syndrome. Circ Res. 2000;87(8):E37-E43.
99. Rook MB, et al. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res. 1999;44(3): 507-517.
100. Watanabe H, et al. Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008;118(6): 2260-2268.
101. Hu D, et al. A mutation in the β3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet. 2009;2(3): 270-278.
102. London B, et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation. 2007;116(20): 2260-2268.
103. Valdivia CR, Ueda K, Ackerman MJ, Makielski JC. GPD1L links redox state to cardiac excitability by PKC-dependent phosphorylation of the sodium channel SCN5A. Am J Physiol Heart Circ Physiol. 2009;297(4):H1446-H1452.
104. Liu M, et al. Cardiac Na+ current regulation by pyridine nucleotides. Circ Res. 2009;105(8): 737-745.
105. Cordeiro JM, Marieb M, Pfeiffer R, Calloe K, Burashnikov E, Antzelevitch C. Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol. 2009;46(5): 695-703.
106. Giudicessi JR, et al. Transient outward current (Ito) gain-of-function mutations in the KCND3- encoded KV4.3 potassium channel and Brugada syndrome. Heart Rhythm. 2011;8(7): 1024-1032.
107. Medeiros-Domingo A, et al. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac KATP channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm. 2010;7(10): 1466-1471.
108. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? Cardiovasc Res. 2005;67(3): 367-378.
109. Tukkie R, Sogaard P, Vleugels J, de Groot IK, Wilde AA, Tan HL. Delay in right ventricular activation contributes to Brugada syndrome. Circulation. 2004;109(10): 1272-1277.
110. Zhang ZS, Tranquillo J, Neplioueva V, Bursac N, Grant AO. Sodium channel kinetic changes that produce Brugada syndrome or progressive cardiac conduction system disease. Am J Physiol Heart Circ Physiol. 2007;292(1):H399-H407.
111. Coronel R, et al. Right ventricular fibrosis and conduction delay in a patient with clinical signs of Brugada syndrome: a combined electrophysiological, genetic, histopathologic, and computational study. Circulation. 2005;112(18): 2769-2777.
112. Postema PG, et al. Slow and discontinuous conduction conspire in Brugada syndrome: a right ventricular mapping and stimulation study. Circ Arrhythm Electrophysiol. 2008;1(5): 379-386.
113. Postema PG, et al. Local depolarization abnormalities are the dominant pathophysiologic mechanism for type 1 electrocardiogram in brugada syndrome a study of electrocardiograms, vectorcardiograms, and body surface potential maps during ajmaline provocation. J Am Coll Cardiol. 2010;55(8): 789-797.
114. Nademanee K, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation. 2011;123(12): 1270-1279.
115. Papadatos GA, et al. Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc Natl Acad Sci U S A. 2002;99(9): 6210-6215.
116. Martin CA, Zhang Y, Grace AA, Huang CL. In vivo studies of Scn5a+/- mice modeling Brugada syndrome demonstrate both conduction and repolarization abnormalities. J Electrocardiol. 2010; 43(5): 433-439.
117. Martin CA, Zhang Y, Grace AA, Huang CL. Increased right ventricular repolarization gradients promote arrhythmogenesis in a murine model of Brugada syndrome. J Cardiovasc Electrophysiol. 2010;21(10): 1153-1159.
118. Liu N, et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res. 2006;99(3): 292-298.
119. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;91(5): 1512-1519.
120. Priori SG, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103(2): 196-200.
121. Lahat H, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69(6): 1378-1384.
122. Roux-Buisson N, et al. Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human. Hum Mol Genet. 2012;21(12): 2759-2767.
123. Curran J, Hinton MJ, Ríos E, Bers DM, Shannon TR. Beta-adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res. 2007;100(3): 391-398.
124. Zhou P, et al. Beta-adrenergic signaling accelerates and synchronizes cardiac ryanodine receptor response to a single L-type Ca2+ channel. Proc Natl Acad Sci U S A. 2009;106(42): 18028-18033.
125. Fernandez-Velasco M, et al. Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2 R4496C underlies catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2009;104(2): 201-209.
126. Knollmann BC, et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest. 2006;116(9): 2510-2520.
127. Rizzi N, et al. Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. Circ Res. 2008;103(3): 298-306.
128. Faggioni M, Knollmann BC. Calsequestrin 2 and arrhythmias. Am J Physiol Heart Circ Physiol. 2012;302(6):H1250-H1260.
129. Chopra N, et al. Ablation of triadin causes loss of cardiac Ca2+ release units, impaired excitation-contraction coupling, and cardiac arrhythmias. Proc Natl Acad Sci U S A. 2009;106(18): 7636-7641.
130. Priori SG, Napolitano C, Di Pasquale E, Condorelli G. Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. J Clin Invest. 2013;123(1): 84-91.